About Us
Pascal Life Sciences is an emerging medtech company pioneering the use of advanced click chemistry to develop a new class of hydrogel therapeutics for improving patient care. The company’s ClickGel platform technology is an injectable, biocompatible, and biodegradable gel with broad clinical potential for local delivery of biologics, antibiotics, and tissue sealants.
Our work is grounded in science, shaped by clinical insight, and driven by a commitment to transform patient lives.
LEADERSHIP
Barbara D. Boyan, Ph.D., Founder, CEO, and Chief Science Officer
Dr. Barbara Boyan is an internationally recognized researcher, academic leader, and serial entrepreneur with a long history of invention, development and commercialization of innovative medical devices. In addition to driving scientific strategy and execution at Pascal, she currently serves as Executive Director of the Institute for Engineering and Medicine at VCU, where she also holds the Alice T. and William H. Goodwin, Jr. Chair in Biomedical Engineering. She previously served as Dean of the VCU College of Engineering and is Professor Emerita at the Georgia Institute of Technology, where she was Associate Dean for Research and Innovation in the College of Engineering. Dr. Boyan has led numerous cross-sector initiatives, including her role as founding director of the FDA-funded Atlanta Pediatric Device Consortium, positioning her at the forefront of regulatory, academic, and industry collaboration.
As a fellow of multiple prestigious scientific societies, a member of Biologics Committee for the North American Spine Society, and former chair of the FDA’s Orthopaedic Device Panel, Dr. Boyan brings expertise in both the science and commercialization of biomedical technologies. She has founded several biomedical technology companies and served on the Boards of public and private companies, as well as not-for-profit organizations. Dr. Boyan has authored more than 540 peer-reviewed papers, reviews, and book chapters, and she holds 24 issued U.S. patents as well as international patents.
Dr. Boyan earned her BA, MA, and PhD in Biology from Rice University, followed by a postdoctoral fellowship in calcification mechanisms at the University of Texas Health Science Center in Houston. She is a fellow in a number of professional organizations, including the National Academy of Inventors, and is a member of the National Academy of Engineering. With over four decades of experience spanning academia, federal regulatory partnerships, and leadership roles in startups, she offers unparalleled skills and insights into navigating the full pathway from innovation to clinical adoption of medical devices.
Barbara D. Boyan, Ph.D., Founder, CEO, and Chief Science Officer
Dr. Barbara Boyan is an internationally recognized researcher, academic leader, and serial entrepreneur with a long history of invention, development and commercialization of innovative medical devices. In addition to driving scientific strategy and execution at Pascal, she currently serves as Executive Director of the Institute for Engineering and Medicine at VCU, where she also holds the Alice T. and William H. Goodwin, Jr. Chair in Biomedical Engineering. She previously served as Dean of the VCU College of Engineering and is Professor Emerita at the Georgia Institute of Technology, where she was Associate Dean for Research and Innovation in the College of Engineering. Dr. Boyan has led numerous cross-sector initiatives, including her role as founding director of the FDA-funded Atlanta Pediatric Device Consortium, positioning her at the forefront of regulatory, academic, and industry collaboration.
As a fellow of multiple prestigious scientific societies, a member of Biologics Committee for the North American Spine Society, and former chair of the FDA’s Orthopaedic Device Panel, Dr. Boyan brings expertise in both the science and commercialization of biomedical technologies. She has founded several biomedical technology companies and served on the Boards of public and private companies, as well as not-for-profit organizations. Dr. Boyan has authored more than 540 peer-reviewed papers, reviews, and book chapters, and she holds 24 issued U.S. patents as well as international patents.
Dr. Boyan earned her BA, MA, and PhD in Biology from Rice University, followed by a postdoctoral fellowship in calcification mechanisms at the University of Texas Health Science Center in Houston. She is a fellow in a number of professional organizations, including the National Academy of Inventors, and is a member of the National Academy of Engineering. With over four decades of experience spanning academia, federal regulatory partnerships, and leadership roles in startups, she offers unparalleled skills and insights into navigating the full pathway from innovation to clinical adoption of medical devices.
Chief Science Officer and Co-Founder
Jim Sevey, COO
Jim Sevey is a distinguished medical device executive with over 25 years of leadership across product development, clinical strategy, and commercialization in the life sciences industry. His expertise spans across multiple industries including medical devices, nanotechnology, biologics, and robotics. As the Chief Operating Officer at Pascal Medical Corporation, he leads operational and regulatory strategy.
His career includes senior leadership roles such as Senior Director of Clinical Strategy at Medtronic, Senior Director of Strategic Partnering and Scientific Field Development at Titan Spine, and Manager Biomaterials Technical Specialist at Depuy/Synthes/Johnson & Johnson. Jim has consistently demonstrated his ability to lead initiatives across biologics, nanotechnology, RF ablation, and predictive analytics, blending technical expertise with market-savvy execution. His skills include driving FDA submissions, clinical science strategy, and market access for cutting-edge spinal and neurosurgical technologies.
Mr. Sevey earned a Bachelor of Science in Health Sciences from Saint Mary’s College of California. He is an active member of ASTM International and a frequent speaker on surface technologies, biomaterials, and evidence-based practice. With a proven track record in both startup growth and corporate M&A environments, he brings invaluable insight to product development, regulatory navigation, and exit strategy planning for early-stage medical device companies.
Jim Sevey, COO
Jim Sevey is a distinguished medical device executive with over 25 years of leadership across product development, clinical strategy, and commercialization in the life sciences industry. His expertise spans across multiple industries including medical devices, nanotechnology, biologics, and robotics. As the Chief Operating Officer at Pascal Medical Corporation, he leads operational and regulatory strategy.
His career includes senior leadership roles such as Senior Director of Clinical Strategy at Medtronic, Senior Director of Strategic Partnering and Scientific Field Development at Titan Spine, and Manager Biomaterials Technical Specialist at Depuy/Synthes/Johnson & Johnson. Jim has consistently demonstrated his ability to lead initiatives across biologics, nanotechnology, RF ablation, and predictive analytics, blending technical expertise with market-savvy execution. His skills include driving FDA submissions, clinical science strategy, and market access for cutting-edge spinal and neurosurgical technologies.
Mr. Sevey earned a Bachelor of Science in Health Sciences from Saint Mary’s College of California. He is an active member of ASTM International and a frequent speaker on surface technologies, biomaterials, and evidence-based practice. With a proven track record in both startup growth and corporate M&A environments, he brings invaluable insight to product development, regulatory navigation, and exit strategy planning for early-stage medical device companies.
COO
Thomas Gardner, Vice President – Finance and Board Member
Mr. Gardner is a seasoned medical device & biotech CEO with more than 37 years of experience in leading innovation-driven startups & corporate turnarounds. He is a recognized expert in the field of physician syndication, having launched over 50 successful, regulatory-compliant physician syndicates. Mr. Gardner is also a strategic authority in clinical trial design and execution, having guided successful approvals in all areas of FDA and international regulatory applications.
As a member of Pascal Medical’s Board, he brings expertise as a founder of 4 public companies and more than 10 private companies, and is a proven exit leader. His leadership has consistently bridged scientific advancement, regulatory compliance, and market strategy, making him a trusted advisor for companies navigating commercialization and growth. Mr. Gardner also currently serves as the President at Gardner Syndication Management, Inc.
Mr. Gardner holds a B.S. in Business Administration and Management from Radford University and an M.A. in Marketing Administration from the University of Denver.
Thomas Gardner, Vice President – Finance and Board Member
Mr. Gardner is a seasoned medical device & biotech CEO with more than 37 years of experience in leading innovation-driven startups & corporate turnarounds. He is a recognized expert in the field of physician syndication, having launched over 50 successful, regulatory-compliant physician syndicates. Mr. Gardner is also a strategic authority in clinical trial design and execution, having guided successful approvals in all areas of FDA and international regulatory applications.
As a member of Pascal Medical’s Board, he brings expertise as a founder of 4 public companies and more than 10 private companies, and is a proven exit leader. His leadership has consistently bridged scientific advancement, regulatory compliance, and market strategy, making him a trusted advisor for companies navigating commercialization and growth. Mr. Gardner also currently serves as the President at Gardner Syndication Management, Inc.
Mr. Gardner holds a B.S. in Business Administration and Management from Radford University and an M.A. in Marketing Administration from the University of Denver.
CEO
Michael C. Mancini, Ph.D., Director of R&D
Dr. Michael Mancini leads research and development at Pascal, where he oversees product development for the company’s flagship ClickGel™ hydrogel technology. His work focuses on optimizing biocompatibility, degradation, and stability of the product while supporting regulatory and manufacturing strategies. Drawing on his experience in material characterization and translational product development, Dr. Mancini plays a central role in guiding ClickGel toward FDA submission and clinical adoption.
Before joining Pascal, Dr. Mancini served as Vice President of R&D at Spectropath, Inc., a company working to commercialize a cancer imaging technology he co-invented during graduate school. While at Spectropath, he developed engineering prototypes, helped secure a $2M seed round, and led early commercial activity, including a $5M pre-sale to a MENA-region distributor. He later served as Vice President of Entrepreneurship and Ecosystem Development at Activation Capital in Richmond, VA, where he designed support infrastructure for high-growth scientific ventures, and previously held academic and tech transfer roles at Virginia Commonwealth University focused on biomedical engineering education and startup formation.
Dr. Mancini holds a BS in Biomedical Engineering from the University of Rochester and a PhD in Biomedical Engineering from the joint Georgia Tech-Emory University program. His academic research contributed to advancements in nanomaterial degradation, intraoperative cancer imaging, and contrast-enhanced diagnostics, authoring multiple publications and patents.
Michael C. Mancini, Ph.D., Director of R&D
Dr. Michael Mancini leads research and development at Pascal, where he oversees product development for the company’s flagship ClickGel™ hydrogel technology. His work focuses on optimizing biocompatibility, degradation, and stability of the product while supporting regulatory and manufacturing strategies. Drawing on his experience in material characterization and translational product development, Dr. Mancini plays a central role in guiding ClickGel toward FDA submission and clinical adoption.
Before joining Pascal, Dr. Mancini served as Vice President of R&D at Spectropath, Inc., a company working to commercialize a cancer imaging technology he co-invented during graduate school. While at Spectropath, he developed engineering prototypes, helped secure a $2M seed round, and led early commercial activity, including a $5M pre-sale to a MENA-region distributor. He later served as Vice President of Entrepreneurship and Ecosystem Development at Activation Capital in Richmond, VA, where he designed support infrastructure for high-growth scientific ventures, and previously held academic and tech transfer roles at Virginia Commonwealth University focused on biomedical engineering education and startup formation.
Dr. Mancini holds a BS in Biomedical Engineering from the University of Rochester and a PhD in Biomedical Engineering from the joint Georgia Tech-Emory University program. His academic research contributed to advancements in nanomaterial degradation, intraoperative cancer imaging, and contrast-enhanced diagnostics, authoring multiple publications and patents.
Director of R&D
ADVISORY BOARD
Paul Slosar, MD, Orthopaedic Spine Surgeon, Former President, SpineCare Medical Group, Former CMO, Titan Spine
Paul Slosar, MD, MHCDS is an orthopedic spine surgeon who practiced for 28 years in the San Francisco Bay area. He served as Administrative Partner and President of SpineCare Medical group from 2007-2020. Dr. Slosar also served as the Medical Director of the Spine Care Institute of San Francisco and Director of Surgical Research at the San Francisco Spine Institute. Dr. Slosar is a Partner at 46 Venture Capital, a multi-fund manager focusing on early-stage investments across multiple sectors. He is a Co-founder and General Partner in their Physicians Capital Fund, launched in 2024, anchored by physician investors focusing on accelerating innovation in healthcare companies. Dr. Slosar has been recognized as one of the Top 100 Spine Surgeons in the United States by Becker’s Orthopedic and Spine Review, as well as a Super Doctor® of San Francisco. He has been named to the prestigious U.S. News & World Report®/ Castle Connolly Top Doctor® list consecutively from 2013-2023.
In 2008, Dr. Slosar became the Chief Medical Officer for Titan Spine, which was acquired by Medtronic in 2019. As the CMO, he provided the company with strategic guidance on spinal implant nano-surface technology development, research publications, as well as interaction with CMS and the FDA. In this capacity, Dr. Slosar has emerged as national expert and frequent lecturer on the topic of emerging spinal implant technologies. He remains a strategy consultant for the Medtronic Neurosciences executive team and is the chairman of their nanotechnology advisory board. From 2020-2023 Dr. Slosar was the Chief Medical Officer for Episode Solutions, a Nashville-based industry leader in value-based health care and bundled payments. Dr. Slosar’s 11-year tenure as CMO of Titan Spine, LLC was pivotal in positioning the company for acquisition by Medtronic in 2019. He has also been a strategic advisor to several other companies which have had successful exits, or acquisitions, including Kyphon (acquired in 2007 by Medtronic) Surgical Care Affiliates (acquired in 2017 by United Health Care/ Optum), and Relievant (acquired in 2023 by Boston Scientific).
In 2021, Dr. Slosar founded PS/md Consulting LLC, providing advisory services to physician practices and healthcare companies. Dr. Slosar holds a Master of Health Care Delivery Science from Dartmouth College, an MD from Rush University, and an Intensive Seminar Certificate in Value Based Health Care from Harvard Business School.
Paul Slosar, MD, Orthopaedic Spine Surgeon, Former President, SpineCare Medical Group, Former CMO, Titan Spine
Paul Slosar, MD, MHCDS is an orthopedic spine surgeon who practiced for 28 years in the San Francisco Bay area. He served as Administrative Partner and President of SpineCare Medical group from 2007-2020. Dr. Slosar also served as the Medical Director of the Spine Care Institute of San Francisco and Director of Surgical Research at the San Francisco Spine Institute. Dr. Slosar is a Partner at 46 Venture Capital, a multi-fund manager focusing on early-stage investments across multiple sectors. He is a Co-founder and General Partner in their Physicians Capital Fund, launched in 2024, anchored by physician investors focusing on accelerating innovation in healthcare companies. Dr. Slosar has been recognized as one of the Top 100 Spine Surgeons in the United States by Becker’s Orthopedic and Spine Review, as well as a Super Doctor® of San Francisco. He has been named to the prestigious U.S. News & World Report®/ Castle Connolly Top Doctor® list consecutively from 2013-2023.
In 2008, Dr. Slosar became the Chief Medical Officer for Titan Spine, which was acquired by Medtronic in 2019. As the CMO, he provided the company with strategic guidance on spinal implant nano-surface technology development, research publications, as well as interaction with CMS and the FDA. In this capacity, Dr. Slosar has emerged as national expert and frequent lecturer on the topic of emerging spinal implant technologies. He remains a strategy consultant for the Medtronic Neurosciences executive team and is the chairman of their nanotechnology advisory board. From 2020-2023 Dr. Slosar was the Chief Medical Officer for Episode Solutions, a Nashville-based industry leader in value-based health care and bundled payments. Dr. Slosar’s 11-year tenure as CMO of Titan Spine, LLC was pivotal in positioning the company for acquisition by Medtronic in 2019. He has also been a strategic advisor to several other companies which have had successful exits, or acquisitions, including Kyphon (acquired in 2007 by Medtronic) Surgical Care Affiliates (acquired in 2017 by United Health Care/ Optum), and Relievant (acquired in 2023 by Boston Scientific).
In 2021, Dr. Slosar founded PS/md Consulting LLC, providing advisory services to physician practices and healthcare companies. Dr. Slosar holds a Master of Health Care Delivery Science from Dartmouth College, an MD from Rush University, and an Intensive Seminar Certificate in Value Based Health Care from Harvard Business School.
Robert Eastlack, MD, Orthopaedic Spine Surgeon, San Diego Spine Foundation, Scripps, La Jolla, CA
Dr. Robert Eastlack serves as Head of the Division of Spine Surgery and directs clinical research for the Department of Orthopaedic Surgery at Scripps Clinic in La Jolla, CA. He additionally co-directs their spine fellowship training program alongside the San Diego Spine Foundation and is a board member of the San Diego Orthopaedic Society.
As a fellow of the Scoliosis Research Society and a member of the International Spine Study Group, Dr. Eastlack brings extensive expertise in minimally invasive spine surgery and research. His research portfolio includes over 100 articles, 175 studies/abstracts to his name, and contributions chapters to 11 books. Dr. Eastlack has also worked within the medical device industry as an inventor, consultant, and serving on numerous medical and scientific advisory boards. He has been an active investor in early-stage medical devices and diagnostics through the founding of his venture fund Baker & Eastlack Ventures.
Dr. Eastlack earned a bachelor’s degree in human biology with a focus on neurophysiology from Stanford University before completing his MD at Baylor College of Medicine. He then completed a residency in orthopaedic surgery at UC San Diego and a spine fellowship at the Mayo Clinic.
Robert Eastlack, MD, Orthopaedic Spine Surgeon, San Diego Spine Foundation, Scripps, La Jolla, CA
Dr. Robert Eastlack serves as Head of the Division of Spine Surgery and directs clinical research for the Department of Orthopaedic Surgery at Scripps Clinic in La Jolla, CA. He additionally co-directs their spine fellowship training program alongside the San Diego Spine Foundation and is a board member of the San Diego Orthopaedic Society.
As a fellow of the Scoliosis Research Society and a member of the International Spine Study Group, Dr. Eastlack brings extensive expertise in minimally invasive spine surgery and research. His research portfolio includes over 100 articles, 175 studies/abstracts to his name, and contributions chapters to 11 books. Dr. Eastlack has also worked within the medical device industry as an inventor, consultant, and serving on numerous medical and scientific advisory boards. He has been an active investor in early-stage medical devices and diagnostics through the founding of his venture fund Baker & Eastlack Ventures.
Dr. Eastlack earned a bachelor’s degree in human biology with a focus on neurophysiology from Stanford University before completing his MD at Baylor College of Medicine. He then completed a residency in orthopaedic surgery at UC San Diego and a spine fellowship at the Mayo Clinic.
Paul Holman, MD, Neurosurgery, Houston Methodist, Houston, TX
Dr. Paul Holman is a board-certified neurosurgeon at Houston Methodist Hospital, where he holds the Houston Methodist Chair in the Spine & Peripheral Nerve Center in the Department of Neurosurgery. He established the first spinal fellowship program in the department as Assistant Professor of Clinical Neurosurgery at the Houston campus of Weill Cornell Medical College. With over 25 years of clinical experience, he specializes in complex techniques such as minimally invasive and image-guided spine surgery, treating a high surgical volume while consistently being recognized for excellence in patient care.
In addition to his clinical practice and roles in resident and fellow education, Dr. Holman is also active in spinal surgery research and innovation, authoring over 20 peer-reviewed publications. He has been instrumental in developing and adopting innovative technologies for complex and minimally invasive spinal surgery, such as 3D spinal navigation systems, lateral fusion surgery, ultrasonic bone-cutting devices, and computer-assisted, preoperative planning software for scoliosis cases.
Dr. Holman received a BS in microbiology from the University of Michigan and his MD from Wayne State University School of Medicine in Detroit. He completed his residency in neurological surgery at the Baylor College of Medicine and an advanced fellowship in spinal surgery at the Cleveland Clinic Lerner College of Medicine.
Paul Holman, MD, Neurosurgery, Houston Methodist, Houston, TX
Dr. Paul Holman is a board-certified neurosurgeon at Houston Methodist Hospital, where he holds the Houston Methodist Chair in the Spine & Peripheral Nerve Center in the Department of Neurosurgery. He established the first spinal fellowship program in the department as Assistant Professor of Clinical Neurosurgery at the Houston campus of Weill Cornell Medical College. With over 25 years of clinical experience, he specializes in complex techniques such as minimally invasive and image-guided spine surgery, treating a high surgical volume while consistently being recognized for excellence in patient care.
In addition to his clinical practice and roles in resident and fellow education, Dr. Holman is also active in spinal surgery research and innovation, authoring over 20 peer-reviewed publications. He has been instrumental in developing and adopting innovative technologies for complex and minimally invasive spinal surgery, such as 3D spinal navigation systems, lateral fusion surgery, ultrasonic bone-cutting devices, and computer-assisted, preoperative planning software for scoliosis cases.
Dr. Holman received a BS in microbiology from the University of Michigan and his MD from Wayne State University School of Medicine in Detroit. He completed his residency in neurological surgery at the Baylor College of Medicine and an advanced fellowship in spinal surgery at the Cleveland Clinic Lerner College of Medicine.
Kade Huntsman, MD, Orthopaedic Spine Surgeon, Huntsman Spine Clinic, Millcreek, UT
Dr. Kade Huntsman is a board-certified orthopaedic spine surgeon with over two decades of experience in complex spinal care, including motion-preserving procedures and regenerative medicine. He serves as co-founder of the Huntsman Spinal Clinic and formerly held the role of Chief of Surgery at St. Mark’s Hospital in Salt Lake City, UT. Performing over 400 spine surgeries annually and authoring over 350 peer-reviewed publications, Dr. Huntsman has built a reputation as a leader in both the operating room and the academic community.
His work has consistently been at the forefront of spinal surgery innovation, including the development and integration of intraoperative imaging, robotics, and novel spinal implants. This clinical experience with advancing technologies, combined with a strong track record of collaboration in research and device development, gives him a practical perspective on evaluating and implementing new solutions for spinal surgery.
Dr. Huntsman holds a bachelor’s degree from the University of Utah in Biology, Chemistry, and Asian Languages and completed his MD at Eastern Virginia Medical School in Hampton Roads, VA. He completed an orthopaedic surgery residency at the Case Western Reserve University School of Medicine followed by a spine fellowship at Rocky Mountain Spine Clinic.
Kade Huntsman, MD, Orthopaedic Spine Surgeon, Huntsman Spine Clinic, Millcreek, UT
Dr. Kade Huntsman is a board-certified orthopaedic spine surgeon with over two decades of experience in complex spinal care, including motion-preserving procedures and regenerative medicine. He serves as co-founder of the Huntsman Spinal Clinic and formerly held the role of Chief of Surgery at St. Mark’s Hospital in Salt Lake City, UT. Performing over 400 spine surgeries annually and authoring over 350 peer-reviewed publications, Dr. Huntsman has built a reputation as a leader in both the operating room and the academic community.
His work has consistently been at the forefront of spinal surgery innovation, including the development and integration of intraoperative imaging, robotics, and novel spinal implants. This clinical experience with advancing technologies, combined with a strong track record of collaboration in research and device development, gives him a practical perspective on evaluating and implementing new solutions for spinal surgery.
Dr. Huntsman holds a bachelor’s degree from the University of Utah in Biology, Chemistry, and Asian Languages and completed his MD at Eastern Virginia Medical School in Hampton Roads, VA. He completed an orthopaedic surgery residency at the Case Western Reserve University School of Medicine followed by a spine fellowship at Rocky Mountain Spine Clinic.
Bruce Mathern, MD, Neurosurgery, VCU Health, Richmond, VA
Dr. Bruce Mathern is a board-certified neurosurgeon, Professor and Vice Chair of the Department of Neurosurgery, Associate Vice President for Managed Care at VCU Health where he has spent over two decades specializing in cranial and spinal procedures. As a neurosurgery faculty member at VCU for almost 30 years, Dr. Mathern has focused on complex spine surgical procedures and has a robust TBI research program.
In his role as AVP for Managed Care at VCU Health, Dr. Mathern bridges clinical practice with operational and reimbursement strategies. He is a key player in the development and implementation of quality-based metrics for physician-informed payer strategy. With his extensive clinical and leadership experience, combined with his expertise in navigating institutional and payer adoption pathways, Dr. Mathern provides valuable insights into medical device product development.
Dr. Mathern earned his BA in chemistry and biology from Case Western Reserve University in Cleveland and obtained his MD at the University of Cincinnati College of Medicine. He completed his residency in neurosurgery at VCU, going on to complete a fellowship in spinal surgery and reconstruction and a Master of Science in Health Administration, also at VCU.
Bruce Mathern, MD, Neurosurgery, VCU Health, Richmond, VA
Dr. Bruce Mathern is a board-certified neurosurgeon, Professor and Vice Chair of the Department of Neurosurgery, Associate Vice President for Managed Care at VCU Health where he has spent over two decades specializing in cranial and spinal procedures. As a neurosurgery faculty member at VCU for almost 30 years, Dr. Mathern has focused on complex spine surgical procedures and has a robust TBI research program.
In his role as AVP for Managed Care at VCU Health, Dr. Mathern bridges clinical practice with operational and reimbursement strategies. He is a key player in the development and implementation of quality-based metrics for physician-informed payer strategy. With his extensive clinical and leadership experience, combined with his expertise in navigating institutional and payer adoption pathways, Dr. Mathern provides valuable insights into medical device product development.
Dr. Mathern earned his BA in chemistry and biology from Case Western Reserve University in Cleveland and obtained his MD at the University of Cincinnati College of Medicine. He completed his residency in neurosurgery at VCU, going on to complete a fellowship in spinal surgery and reconstruction and a Master of Science in Health Administration, also at VCU.
Ziev Moses, MD, Neurosurgery, Beth Israel Deaconess Medical Center, Boston, MA
Dr. Ziev Moses is a board-certified neurosurgeon practicing at Beth Israel Deaconess Medical Center in Boston and Assistant Professor of Neurosurgery at Harvard Medical School. With a focus on complex and degenerative spine conditions, such as disc arthroplasty, spinal fusion, minimally invasive and robotic spine surgery, spinal cord injury, tumors, and traumatic brain injury, he brings a breadth of surgical expertise across a high volume of cases annually.
Dr. Moses maintains a strong academic and research presence, authoring 36 publications on advanced topics such as MRI-guided cryoablation for spinal tumors. His experience in surgical innovation and translational research equips him with insightful guidance on emerging spinal therapies and minimally invasive surgical interfaces.
Dr. Moses earned his BS in bioengineering and biomedical engineering from Tulane University and his MD from the Geisel School of Medicine at Dartmouth. He then completed a neurosurgery residency at both Brigham and Women’s Hospital and Boston Children’s Hospital followed by a neurosurgery spine fellowship at Rush University.
Ziev Moses, MD, Neurosurgery, Beth Israel Deaconess Medical Center, Boston, MA
Dr. Ziev Moses is a board-certified neurosurgeon practicing at Beth Israel Deaconess Medical Center in Boston and Assistant Professor of Neurosurgery at Harvard Medical School. With a focus on complex and degenerative spine conditions, such as disc arthroplasty, spinal fusion, minimally invasive and robotic spine surgery, spinal cord injury, tumors, and traumatic brain injury, he brings a breadth of surgical expertise across a high volume of cases annually.
Dr. Moses maintains a strong academic and research presence, authoring 36 publications on advanced topics such as MRI-guided cryoablation for spinal tumors. His experience in surgical innovation and translational research equips him with insightful guidance on emerging spinal therapies and minimally invasive surgical interfaces.
Dr. Moses earned his BS in bioengineering and biomedical engineering from Tulane University and his MD from the Geisel School of Medicine at Dartmouth. He then completed a neurosurgery residency at both Brigham and Women’s Hospital and Boston Children’s Hospital followed by a neurosurgery spine fellowship at Rush University.
Kieran Murphy, MD, Interventional Radiology, University Health Network, Toronto, CAN
Dr. Kieran Murphy is a distinguished interventional neuroradiologist at Toronto Western Hospital where he treats over 300 complex spine and neurovascular cases annually using advanced image-guided techniques. Also, as a professor at the University Health Network in Toronto, he has authored more than 170 peer-reviewed articles and earned international recognition as an innovator in interventional radiology research. He previously led the division of interventional neuroradiology at Johns Hopkins University for a decade.
A prolific innovator, Dr. Murphy holds over 80 patents related to spine intervention devices, such as vertebroplasty tools now used in thousands of hospitals worldwide and has founded multiple medical device companies. Dr. Murphy brings vast experience in translating research into clinical practice, making him well-positioned to evaluate and guide the development of novel technologies for spinal applications.
Dr. Murphy graduated from the Royal College of Surgeons in Ireland, completing residency and a neuroradiology fellowship at the University of Michigan, and an interventional neuroradiology fellowship at the University of Geneva.
Kieran Murphy, MD, Interventional Radiology, University Health Network, Toronto, CAN
Dr. Kieran Murphy is a distinguished interventional neuroradiologist at Toronto Western Hospital where he treats over 300 complex spine and neurovascular cases annually using advanced image-guided techniques. Also, as a professor at the University Health Network in Toronto, he has authored more than 170 peer-reviewed articles and earned international recognition as an innovator in interventional radiology research. He previously led the division of interventional neuroradiology at Johns Hopkins University for a decade.
A prolific innovator, Dr. Murphy holds over 80 patents related to spine intervention devices, such as vertebroplasty tools now used in thousands of hospitals worldwide and has founded multiple medical device companies. Dr. Murphy brings vast experience in translating research into clinical practice, making him well-positioned to evaluate and guide the development of novel technologies for spinal applications.
Dr. Murphy graduated from the Royal College of Surgeons in Ireland, completing residency and a neuroradiology fellowship at the University of Michigan, and an interventional neuroradiology fellowship at the University of Geneva.
Peter Ullrich, MD, Orthopaedic Spine Surgeon, CEO and Co-Founder, Titan Spine, acquired by Medtronic
Dr. Peter Ullrich is a retired orthopaedic spine surgeon and medical device entrepreneur with over 30 years of experience in spinal surgery, innovation, and commercialization. He is the co-founder and former CEO of Titan Spine; a spinal implant company focused on surface technology and interbody fusion devices. Under his leadership, Titan Spine grew from a concept-stage startup to a leading innovator in the spinal implant market, ultimately being acquired by Medtronic in 2019. Dr. Ullrich also founded the NeuroSpine Center of Wisconsin and Veritas Health, an online publishing company specializing in patient education.
As both a physician and founder, Dr. Ullrich brings a perspective to the medical device development that spans the clinical, technical, and business dimensions of the industry. His background equips him with insights from clinical need identification, navigating FDA regulatory processes, facilitating product adoption, surgeon education, and negotiating market exit strategies.
Dr. Ullrich received a BA from Marquette University in Wisconsin and his MD from the University of Wisconsin Medical School. He completed his orthopaedic surgery residency at Corewell Health in Michigan, followed by a spine surgery fellowship at the University of Utah.
Peter Ullrich, MD, Orthopaedic Spine Surgeon, CEO and Co-Founder, Titan Spine, acquired by Medtronic
Dr. Peter Ullrich is a retired orthopaedic spine surgeon and medical device entrepreneur with over 30 years of experience in spinal surgery, innovation, and commercialization. He is the co-founder and former CEO of Titan Spine; a spinal implant company focused on surface technology and interbody fusion devices. Under his leadership, Titan Spine grew from a concept-stage startup to a leading innovator in the spinal implant market, ultimately being acquired by Medtronic in 2019. Dr. Ullrich also founded the NeuroSpine Center of Wisconsin and Veritas Health, an online publishing company specializing in patient education.
As both a physician and founder, Dr. Ullrich brings a perspective to the medical device development that spans the clinical, technical, and business dimensions of the industry. His background equips him with insights from clinical need identification, navigating FDA regulatory processes, facilitating product adoption, surgeon education, and negotiating market exit strategies.
Dr. Ullrich received a BA from Marquette University in Wisconsin and his MD from the University of Wisconsin Medical School. He completed his orthopaedic surgery residency at Corewell Health in Michigan, followed by a spine surgery fellowship at the University of Utah.
Marjorie Wang, MD, Neurosurgery, Medical College of Wisconsin, Milwaukee, WI
Dr. Marjorie Wang is a board-certified neurosurgeon, Professor of Neurosurgery and Director of the Complex Spine Fellowship Program at the Medical College of Wisconsin and serves as the Executive Director of the American Board of Neurological Surgery. She previously served as the Chief Clinical Transformation Officer at the MCW, working to align clinical innovation with organizational strategy.
Clinically, Dr. Wang focuses on complex spine pathology, including spinal fusion, arthroplasty, decompression, image-guided, minimally invasive, and robotic spine surgery. Her prolific research output includes studies on cervical myelopathy outcomes, health services utilization, and postoperative recovery. With over 80 peer-reviewed publications, strong citation impact, and active roles in clinical trial development and fellowship training, she brings both technical depth and passion for leadership.
Dr. Wang earned a BA in biology from Brown University and obtained her MD from Loyola Stritch School of Medicine in Chicago. She completed a residency in neurosurgery at the University of Colorado in Denver and earned an MPH from the University of Washington School of Public Health before completing a complex spine fellowship at MCW.
Marjorie Wang, MD, Neurosurgery, Medical College of Wisconsin, Milwaukee, WI
Dr. Marjorie Wang is a board-certified neurosurgeon, Professor of Neurosurgery and Director of the Complex Spine Fellowship Program at the Medical College of Wisconsin and serves as the Executive Director of the American Board of Neurological Surgery. She previously served as the Chief Clinical Transformation Officer at the MCW, working to align clinical innovation with organizational strategy.
Clinically, Dr. Wang focuses on complex spine pathology, including spinal fusion, arthroplasty, decompression, image-guided, minimally invasive, and robotic spine surgery. Her prolific research output includes studies on cervical myelopathy outcomes, health services utilization, and postoperative recovery. With over 80 peer-reviewed publications, strong citation impact, and active roles in clinical trial development and fellowship training, she brings both technical depth and passion for leadership.
Dr. Wang earned a BA in biology from Brown University and obtained her MD from Loyola Stritch School of Medicine in Chicago. She completed a residency in neurosurgery at the University of Colorado in Denver and earned an MPH from the University of Washington School of Public Health before completing a complex spine fellowship at MCW.
Joseph K. Williams, MD
Pediatric Craniofacial Surgery, Children’s Healthcare of Atlanta & Emory, Atlanta, GA
Dr. Joseph K. Williams is a board-certified plastic and reconstructive surgeon, Chief of Plastic & Craniofacial Surgery at Children’s Healthcare of Atlanta and serves as Clinical Research Director of the Center for Craniofacial Disorders. He also holds an academic appointment as Associate Professor in the Division of Plastic Surgery and Adjunct Professor in the Department of Pediatrics at Emory University School of Medicine.
As a prolific clinician-researcher, Dr. Williams has authored over 40 peer-reviewed publications and has led initiatives such as implementing Enhanced Recovery after Surgery (ERAS) protocols for pediatric patients undergoing cleft palate repair, yielding improved pain control and reduced hospital stays. He also brings leadership experience from his active roles in the American Society of Plastic Surgery, American Cleft Palate-Craniofacial Association, and the American Society of Maxillofacial Surgery.
Dr. Williams obtained his MD at the University of Mississippi School of Medicine and completed his residency in plastic surgery at Emory University. After, he finished his training as a fellow in pediatric and craniofacial surgery at the New York University School of Medicine.
Joseph K. Williams, MD
Pediatric Craniofacial Surgery, Children’s Healthcare of Atlanta & Emory, Atlanta, GA
Dr. Joseph K. Williams is a board-certified plastic and reconstructive surgeon, Chief of Plastic & Craniofacial Surgery at Children’s Healthcare of Atlanta and serves as Clinical Research Director of the Center for Craniofacial Disorders. He also holds an academic appointment as Associate Professor in the Division of Plastic Surgery and Adjunct Professor in the Department of Pediatrics at Emory University School of Medicine.
As a prolific clinician-researcher, Dr. Williams has authored over 40 peer-reviewed publications and has led initiatives such as implementing Enhanced Recovery after Surgery (ERAS) protocols for pediatric patients undergoing cleft palate repair, yielding improved pain control and reduced hospital stays. He also brings leadership experience from his active roles in the American Society of Plastic Surgery, American Cleft Palate-Craniofacial Association, and the American Society of Maxillofacial Surgery.
Dr. Williams obtained his MD at the University of Mississippi School of Medicine and completed his residency in plastic surgery at Emory University. After, he finished his training as a fellow in pediatric and craniofacial surgery at the New York University School of Medicine.
Vishal Yajnik, MD, Medical Director, Neuroscience Intensive Care Unit, VCU Health, Richmond, VA
Dr. Vishal Yajnik is Associate Professor and Medical Director of the Neuroscience Intensive Care Unit at VCU Health, within the Department of Anesthesiology. He leads a multidisciplinary team within Virginia’s largest NSICU that manages life-threatening neurological and spinal conditions around the clock, ensuring innovation initiatives are strategically aligned with core clinical operations.
As a specialist in neurocritical care, Dr. Yajnik focuses on improving patient outcomes through advancing treatment protocols, his clinical responsibilities include treating intracranial hemorrhage, TBI, spinal cord injury, strokes, post-operative neurosurgical recovery, and infections of the central nervous system. Dr. Yajnik is also involved in clinical research through VCU Health with over 10 peer-reviewed publications and experience as the former vice chair of the university’s Institutional Review Board, bringing in extensive knowledge of clinical research ethics, regulatory compliance, and trial design.
Dr. Yajnik completed his undergraduate education at Johns Hopkins University, earning a BA in public health. He has an MS in physiology & biophysics from Georgetown and his MD from the VCU School of Medicine. He completed his residency in anesthesiology at the VCU Medical Center, followed by a fellowship in critical care medicine at the University of Pittsburgh Medical Center.
Vishal Yajnik, MD, Medical Director, Neuroscience Intensive Care Unit, VCU Health, Richmond, VA
Dr. Vishal Yajnik is Associate Professor and Medical Director of the Neuroscience Intensive Care Unit at VCU Health, within the Department of Anesthesiology. He leads a multidisciplinary team within Virginia’s largest NSICU that manages life-threatening neurological and spinal conditions around the clock, ensuring innovation initiatives are strategically aligned with core clinical operations.
As a specialist in neurocritical care, Dr. Yajnik focuses on improving patient outcomes through advancing treatment protocols, his clinical responsibilities include treating intracranial hemorrhage, TBI, spinal cord injury, strokes, post-operative neurosurgical recovery, and infections of the central nervous system. Dr. Yajnik is also involved in clinical research through VCU Health with over 10 peer-reviewed publications and experience as the former vice chair of the university’s Institutional Review Board, bringing in extensive knowledge of clinical research ethics, regulatory compliance, and trial design.
Dr. Yajnik completed his undergraduate education at Johns Hopkins University, earning a BA in public health. He has an MS in physiology & biophysics from Georgetown and his MD from the VCU School of Medicine. He completed his residency in anesthesiology at the VCU Medical Center, followed by a fellowship in critical care medicine at the University of Pittsburgh Medical Center.
RESEARCH & DEVELOPMENT TEAM
D. Joshua Cohen, M.D., Consultant, Animal Models
Dr. Cohen is a physician-scientist and Research Assistant Professor of Biomedical Engineering at Virginia Commonwealth University, where he specializes in preclinical model development for musculoskeletal and biomaterials research. As a core member of the Pascal development team, he leads the design and execution of in vivo studies to evaluate biocompatibility and efficacy, with a focus on advancing ClickGel toward an FDA IDE submission. His expertise includes orthopaedic implant evaluation, hydrogel testing, and regulatory-aligned GLP animal studies. His training and experience at the intersection of medicine, biomaterials, and translational science make him a vital contributor.
Dr. Cohen currently chairs VCU’s Institutional Animal Care and Use Committee and has held leadership roles in the Orthopaedic Research Society focused on preclinical standards. He holds a BS in both Biology and Political Science and earned his MD from Universidad Iberoamericana. Dr. Cohen completed advanced research fellowships in biomedical engineering at Georgia Tech and Virginia Commonwealth University.
D. Joshua Cohen, M.D., Consultant, Animal Models
Dr. Cohen is a physician-scientist and Research Assistant Professor of Biomedical Engineering at Virginia Commonwealth University, where he specializes in preclinical model development for musculoskeletal and biomaterials research. As a core member of the Pascal development team, he leads the design and execution of in vivo studies to evaluate biocompatibility and efficacy, with a focus on advancing ClickGel toward an FDA IDE submission. His expertise includes orthopaedic implant evaluation, hydrogel testing, and regulatory-aligned GLP animal studies. His training and experience at the intersection of medicine, biomaterials, and translational science make him a vital contributor.
Dr. Cohen currently chairs VCU’s Institutional Animal Care and Use Committee and has held leadership roles in the Orthopaedic Research Society focused on preclinical standards. He holds a BS in both Biology and Political Science and earned his MD from Universidad Iberoamericana. Dr. Cohen completed advanced research fellowships in biomedical engineering at Georgia Tech and Virginia Commonwealth University.
George Delli-Santi, Consultant, Engineering
George Delli-Santi is a medical device engineer with over 40 years of experience in biomaterials, product development, and manufacturing process design. As an engineering consultant for Pascal, he applies expertise in hydrogel chemistry, orthopaedic biomaterials, and surgical device manufacturing gained through senior R&D roles at companies including Norian, Kyphon, Parallax Medical, ArthroCare, and Smith & Nephew. He has led large-scale manufacturing projects, developed proprietary bioresorbable and cellulosic hydrogel systems, and holds multiple patents for surgical and implant technologies.
George’s background in design, regulatory compliance, and process scale-up makes him a valuable contributor to Pascal’s product development and commercialization strategy. George earned his BS and ME in Biomedical Engineering from Rensselaer Polytechnic Institute.
George Delli-Santi, Consultant, Engineering
George Delli-Santi is a medical device engineer with over 40 years of experience in biomaterials, product development, and manufacturing process design. As an engineering consultant for Pascal, he applies expertise in hydrogel chemistry, orthopaedic biomaterials, and surgical device manufacturing gained through senior R&D roles at companies including Norian, Kyphon, Parallax Medical, ArthroCare, and Smith & Nephew. He has led large-scale manufacturing projects, developed proprietary bioresorbable and cellulosic hydrogel systems, and holds multiple patents for surgical and implant technologies.
George’s background in design, regulatory compliance, and process scale-up makes him a valuable contributor to Pascal’s product development and commercialization strategy. George earned his BS and ME in Biomedical Engineering from Rensselaer Polytechnic Institute.
John Souza, Consultant, Applicator Design
John Souza is an experienced mechanical engineer with nearly two decades of experience developing implant and instrument systems for the orthopaedic industry. He is the CEO of Wheelhouse Medical, a Charlotte-based medical device design and development firm, and serves as a consultant for Pascal on applicator design. His past leadership roles include Director of Engineering at Cutting Edge Spine and Integrity Implants, where he led the development of innovative surgical systems from concept through commercialization.
His expertise in precision engineering, device ergonomics, and complex surgical instrument design makes him a key contributor to Pascal’s product development efforts. John holds multiple patents for orthopaedic spine surgical instruments and earned his MS in Mechanical Engineering from the University of North Carolina at Charlotte.
John Souza, Consultant, Applicator Design
John Souza is an experienced mechanical engineer with nearly two decades of experience developing implant and instrument systems for the orthopaedic industry. He is the CEO of Wheelhouse Medical, a Charlotte-based medical device design and development firm, and serves as a consultant for Pascal on applicator design. His past leadership roles include Director of Engineering at Cutting Edge Spine and Integrity Implants, where he led the development of innovative surgical systems from concept through commercialization.
His expertise in precision engineering, device ergonomics, and complex surgical instrument design makes him a key contributor to Pascal’s product development efforts. John holds multiple patents for orthopaedic spine surgical instruments and earned his MS in Mechanical Engineering from the University of North Carolina at Charlotte.
Monique van Hoek, Ph.D., Consultant, Antimicrobials
Dr. Monique van Hoek is a professor of Microbiology and Infectious Diseases and serves as Co-Director of the Center for Infectious Disease Research at George Mason University. As a consultant at Pascal, she brings extensive expertise in antimicrobial agents targeting drug-resistant pathogens. She has led multiple federally funded projects, including a $2M Joint Warfighter grant to advance new antimicrobial therapeutics through pre-clinical development.
With over 60 peer-reviewed publications, five patents, and decades of translational research experience, Dr. van Hoek is internationally recognized for her contributions to infectious disease innovation. She earned her PhD in Microbiology from the University of Virginia and a BA in Biochemistry from the University of Victoria.
Monique van Hoek, Ph.D., Consultant, Antimicrobials
Dr. Monique van Hoek is a professor of Microbiology and Infectious Diseases and serves as Co-Director of the Center for Infectious Disease Research at George Mason University. As a consultant at Pascal, she brings extensive expertise in antimicrobial agents targeting drug-resistant pathogens. She has led multiple federally funded projects, including a $2M Joint Warfighter grant to advance new antimicrobial therapeutics through pre-clinical development.
With over 60 peer-reviewed publications, five patents, and decades of translational research experience, Dr. van Hoek is internationally recognized for her contributions to infectious disease innovation. She earned her PhD in Microbiology from the University of Virginia and a BA in Biochemistry from the University of Victoria.
Lilian Jones, Intern, Finance & Business Development
Lilian is a recent graduate from the University of Virginia’s McIntire School of Commerce with an MS in Commerce, specializing in biotechnology, and holds a BS in Biomedical Engineering, also from UVA.
Lilian Jones, Intern, Finance & Business Development
Lilian is a recent graduate from the University of Virginia’s McIntire School of Commerce with an MS in Commerce, specializing in biotechnology, and holds a BS in Biomedical Engineering, also from UVA.
Ignacio Moyano, Intern, R&D
Ignacio is a recent graduate of VCU with a BS in Biomedical Engineering, where he was an undergraduate researcher in Dr. Rebecca Heise’s Pulmonary Mechanobiology Lab and mentored by Dr. Boyan for his senior capstone project.
Ignacio Moyano, Intern, R&D
Ignacio is a recent graduate of VCU with a BS in Biomedical Engineering, where he was an undergraduate researcher in Dr. Rebecca Heise’s Pulmonary Mechanobiology Lab and mentored by Dr. Boyan for his senior capstone project.
Trevor Pearce, Intern, Market Research
Trevor is a graduate of the Georgia Institute of Technology’s Master of Biomedical Innovation and Development program and earned his BS in Biomedical Engineering from the University of California, Irvine.
Trevor Pearce, Intern, Market Research
Trevor is a graduate of the Georgia Institute of Technology’s Master of Biomedical Innovation and Development program and earned his BS in Biomedical Engineering from the University of California, Irvine.
BOARD OF DIRECTORS
Gregg Smart, M.B.A., Chairman of the Board
Gregg Smart is an accomplished private equity investor and strategic advisor with over 35 years of experience in capital markets, M&A, and middle-market investing. As a member of Pascal Medical’s Board of Directors, he brings expertise in deal structuring, capital strategy, and governance to support the company’s growth and commercialization of ClickGel. His insight into operational execution and financial scaling is instrumental as Pascal transitions from early-stage to market readiness.
Gregg has privately invested in opportunities across the Southeast since 2019. He was a general partner at Fenway Partners LLC, a middle-market private equity firm with control investments in consumer, light manufacturing, distribution and logistics. At Fenway, he led deal sourcing and structuring, portfolio oversight, capital raising, and firm administration, serving as a board director for multiple portfolio companies.
Earlier in his career, Gregg spent over a decade at Merrill Lynch & Co. in New York City as an investment banker, where he held leadership roles in corporate and leveraged finance, ultimately serving as Managing Director covering private equity clients. Gregg holds a BA in Economics from Davidson College and earned his MBA from The Wharton School of Business at the University of Pennsylvania.
Gregg Smart, M.B.A., Chairman of the Board
Gregg Smart is an accomplished private equity investor and strategic advisor with over 35 years of experience in capital markets, M&A, and middle-market investing. As a member of Pascal Medical’s Board of Directors, he brings expertise in deal structuring, capital strategy, and governance to support the company’s growth and commercialization of ClickGel. His insight into operational execution and financial scaling is instrumental as Pascal transitions from early-stage to market readiness.
Gregg has privately invested in opportunities across the Southeast since 2019. He was a general partner at Fenway Partners LLC, a middle-market private equity firm with control investments in consumer, light manufacturing, distribution and logistics. At Fenway, he led deal sourcing and structuring, portfolio oversight, capital raising, and firm administration, serving as a board director for multiple portfolio companies.
Earlier in his career, Gregg spent over a decade at Merrill Lynch & Co. in New York City as an investment banker, where he held leadership roles in corporate and leveraged finance, ultimately serving as Managing Director covering private equity clients. Gregg holds a BA in Economics from Davidson College and earned his MBA from The Wharton School of Business at the University of Pennsylvania.
Barbara D. Boyan, Ph.D., Founder, CEO, President, and Board Chair
Dr. Barbara Boyan is an internationally recognized researcher, academic leader, and serial entrepreneur with a long history of invention, development and commercialization of innovative medical devices. In addition to driving scientific strategy and execution at Pascal, she currently serves as Executive Director of the Institute for Engineering and Medicine at VCU, where she also holds the Alice T. and William H. Goodwin, Jr. Chair in Biomedical Engineering. She previously served as Dean of the VCU College of Engineering and is Professor Emerita at the Georgia Institute of Technology, where she was Associate Dean for Research and Innovation in the College of Engineering. Dr. Boyan has led numerous cross-sector initiatives, including her role as founding director of the FDA-funded Atlanta Pediatric Device Consortium, positioning her at the forefront of regulatory, academic, and industry collaboration.
As a fellow of multiple prestigious scientific societies, a member of Biologics Committee for the North American Spine Society, and former chair of the FDA’s Orthopaedic Device Panel, Dr. Boyan brings expertise in both the science and commercialization of biomedical technologies. She has founded several biomedical technology companies and served on the Boards of public and private companies, as well as not-for-profit organizations. Dr. Boyan has authored more than 540 peer-reviewed papers, reviews, and book chapters, and she holds 24 issued U.S. patents as well as international patents.
Dr. Boyan earned her BA, MA, and PhD in Biology from Rice University, followed by a postdoctoral fellowship in calcification mechanisms at the University of Texas Health Science Center in Houston. She is a fellow in a number of professional organizations, including the National Academy of Inventors, and is a member of the National Academy of Engineering. With over four decades of experience spanning academia, federal regulatory partnerships, and leadership roles in startups, she offers unparalleled skills and insights into navigating the full pathway from innovation to clinical adoption of medical devices.
Barbara D. Boyan, Ph.D., Founder, CEO, President, and Board Chair
Dr. Barbara Boyan is an internationally recognized researcher, academic leader, and serial entrepreneur with a long history of invention, development and commercialization of innovative medical devices. In addition to driving scientific strategy and execution at Pascal, she currently serves as Executive Director of the Institute for Engineering and Medicine at VCU, where she also holds the Alice T. and William H. Goodwin, Jr. Chair in Biomedical Engineering. She previously served as Dean of the VCU College of Engineering and is Professor Emerita at the Georgia Institute of Technology, where she was Associate Dean for Research and Innovation in the College of Engineering. Dr. Boyan has led numerous cross-sector initiatives, including her role as founding director of the FDA-funded Atlanta Pediatric Device Consortium, positioning her at the forefront of regulatory, academic, and industry collaboration.
As a fellow of multiple prestigious scientific societies, a member of Biologics Committee for the North American Spine Society, and former chair of the FDA’s Orthopaedic Device Panel, Dr. Boyan brings expertise in both the science and commercialization of biomedical technologies. She has founded several biomedical technology companies and served on the Boards of public and private companies, as well as not-for-profit organizations. Dr. Boyan has authored more than 540 peer-reviewed papers, reviews, and book chapters, and she holds 24 issued U.S. patents as well as international patents.
Dr. Boyan earned her BA, MA, and PhD in Biology from Rice University, followed by a postdoctoral fellowship in calcification mechanisms at the University of Texas Health Science Center in Houston. She is a fellow in a number of professional organizations, including the National Academy of Inventors, and is a member of the National Academy of Engineering. With over four decades of experience spanning academia, federal regulatory partnerships, and leadership roles in startups, she offers unparalleled skills and insights into navigating the full pathway from innovation to clinical adoption of medical devices.
Thomas Gardner
Mr. Gardner is a seasoned medical device & biotech CEO with more than 37 years of experience in leading innovation-driven startups & corporate turnarounds. He is a recognized expert in the field of physician syndication, having launched over 50 successful, regulatory-compliant physician syndicates. Mr. Gardner is also a strategic authority in clinical trial design and execution, having guided successful approvals in all areas of FDA and international regulatory applications.
As a member of Pascal Medical’s Board, he brings expertise as a founder of 4 public companies and more than 10 private companies, and is a proven exit leader. His leadership has consistently bridged scientific advancement, regulatory compliance, and market strategy, making him a trusted advisor for companies navigating commercialization and growth. Mr. Gardner also currently serves as the President at Gardner Syndication Management, Inc.
Mr. Gardner holds a B.S. in Business Administration and Management from Radford University and an M.A. in Marketing Administration from the University of Denver.
Thomas Gardner
Mr. Gardner is a seasoned medical device & biotech CEO with more than 37 years of experience in leading innovation-driven startups & corporate turnarounds. He is a recognized expert in the field of physician syndication, having launched over 50 successful, regulatory-compliant physician syndicates. Mr. Gardner is also a strategic authority in clinical trial design and execution, having guided successful approvals in all areas of FDA and international regulatory applications.
As a member of Pascal Medical’s Board, he brings expertise as a founder of 4 public companies and more than 10 private companies, and is a proven exit leader. His leadership has consistently bridged scientific advancement, regulatory compliance, and market strategy, making him a trusted advisor for companies navigating commercialization and growth. Mr. Gardner also currently serves as the President at Gardner Syndication Management, Inc.
Mr. Gardner holds a B.S. in Business Administration and Management from Radford University and an M.A. in Marketing Administration from the University of Denver.
Richard Hall, Board Member
Richard is a seasoned executive, investor, and strategic advisor with more than 25 years of experience spanning private equity, startup growth, and public service. As a co-founder of Pascal, he has played a central role in shaping the company’s vision and securing over $9 million in combined non-dilutive and private capital to advance ClickGel™, Pascal’s flagship injectable hydrogel for dural repair. He provides guidance across corporate governance, financial strategy, and commercial planning.
Throughout his career, Richard has held executive and investment leadership roles across a range of industries. He co-founded Commonwealth Laminating & Coating, which scaled into a $125M global manufacturing enterprise and the largest private employer in its region prior to acquisition. As a principal at Orion Capital, he focuses on value creation through rigorous diligence, governance, capital structuring, and operational turnaround leadership. His work consistently bridges financial acumen with mission-driven execution in high-growth environments.
In addition to his business leadership, Richard has served for more than a decade in appointed roles that support innovation and economic development in Virginia. He currently serves as Chair of the Governance Committee for the Virginia Innovation Partnership Authority and has held leadership positions on the New College Institute Board of Directors. Richard holds a bachelor’s degree in finance from Virginia Tech.
Richard Hall, Board Member
Richard is a seasoned executive, investor, and strategic advisor with more than 25 years of experience spanning private equity, startup growth, and public service. As a co-founder of Pascal, he has played a central role in shaping the company’s vision and securing over $9 million in combined non-dilutive and private capital to advance ClickGel™, Pascal’s flagship injectable hydrogel for dural repair. He provides guidance across corporate governance, financial strategy, and commercial planning.
Throughout his career, Richard has held executive and investment leadership roles across a range of industries. He co-founded Commonwealth Laminating & Coating, which scaled into a $125M global manufacturing enterprise and the largest private employer in its region prior to acquisition. As a principal at Orion Capital, he focuses on value creation through rigorous diligence, governance, capital structuring, and operational turnaround leadership. His work consistently bridges financial acumen with mission-driven execution in high-growth environments.
In addition to his business leadership, Richard has served for more than a decade in appointed roles that support innovation and economic development in Virginia. He currently serves as Chair of the Governance Committee for the Virginia Innovation Partnership Authority and has held leadership positions on the New College Institute Board of Directors. Richard holds a bachelor’s degree in finance from Virginia Tech.
Rob Quartel, M.P.P.M., Board Member
Rob Quartel is a nationally recognized expert in U.S. transportation, maritime policy, and public sector innovation, with a career spanning public service, entrepreneurship, and policy leadership. As a member of Pascal’s Board of Directors, he provides strategic guidance informed by decades of experience in regulatory policy, government operations, and startup formation across both public and private sectors. His work supports Pascal’s mission to advance breakthrough biomaterials by connecting regulatory strategy with market opportunity.
Rob’s career includes senior roles in four private-sector and three government startup ventures, as well as advisory positions in multiple presidential campaigns. He served as a member of the U.S. Federal Maritime Commission and has been a key advisor to Congress and numerous senior public figures on issues ranging from homeland security to food safety, logistics, and transportation infrastructure. In addition to founding and leading the decision-support technology company NTELX, he actively mentors early-stage entrepreneurs through Yale, Rice, and various regional innovation networks.
Rob holds a BA in Biology from Rice University and a master’s degree in Public and Private Management from the Yale School of Management. He also serves as a member of the Council on Foreign Relations.
Rob Quartel, M.P.P.M., Board Member
Rob Quartel is a nationally recognized expert in U.S. transportation, maritime policy, and public sector innovation, with a career spanning public service, entrepreneurship, and policy leadership. As a member of Pascal’s Board of Directors, he provides strategic guidance informed by decades of experience in regulatory policy, government operations, and startup formation across both public and private sectors. His work supports Pascal’s mission to advance breakthrough biomaterials by connecting regulatory strategy with market opportunity.
Rob’s career includes senior roles in four private-sector and three government startup ventures, as well as advisory positions in multiple presidential campaigns. He served as a member of the U.S. Federal Maritime Commission and has been a key advisor to Congress and numerous senior public figures on issues ranging from homeland security to food safety, logistics, and transportation infrastructure. In addition to founding and leading the decision-support technology company NTELX, he actively mentors early-stage entrepreneurs through Yale, Rice, and various regional innovation networks.
Rob holds a BA in Biology from Rice University and a master’s degree in Public and Private Management from the Yale School of Management. He also serves as a member of the Council on Foreign Relations.
NEWS
